|Bid||61.38 x 800|
|Ask||62.10 x 200|
|Day's Range||61.43 - 62.04|
|52 Week Range||58.29 - 66.80|
|PE Ratio (TTM)||39.50|
|Dividend & Yield||1.88 (3.06%)|
|1y Target Est||N/A|
Zoetis, Inc. (ZTS) expects to witness stronger growth from its companion animal portfolio in 2017 driven by its dermatology portfolio, Apoquel and Cytopoint, further penetration of Simparica,
Two French scientists are suing Delaware because the state sold stock they owned in Idenix Pharmaceuticals without telling them. The case has implications across the U.S. as many companies are incorporated ...
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.